118 related articles for article (PubMed ID: 14997342)
1. Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates.
Thompson PA; Berg SL; Aleksic A; Kerr JZ; McGuffey L; Dauser R; Nuchtern JG; Hausheer F; Blaney SM
Cancer Chemother Pharmacol; 2004 Jun; 53(6):527-32. PubMed ID: 14997342
[TBL] [Abstract][Full Text] [Related]
2. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates.
Blaney SM; Cole DE; Balis FM; Godwin K; Poplack DG
Cancer Res; 1993 Feb; 53(4):725-7. PubMed ID: 8428353
[TBL] [Abstract][Full Text] [Related]
3. Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates.
Renbarger J; Aleksic A; McGuffey L; Dauser R; Berg S; Blaney S
Cancer Chemother Pharmacol; 2004 Jan; 53(1):39-42. PubMed ID: 14551735
[TBL] [Abstract][Full Text] [Related]
4. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates.
Blaney SM; Takimoto C; Murry DJ; Kuttesch N; McCully C; Cole DE; Godwin K; Balis FM
Cancer Chemother Pharmacol; 1998; 41(6):464-8. PubMed ID: 9554590
[TBL] [Abstract][Full Text] [Related]
5. A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid.
Sung C; Blaney SM; Cole DE; Balis FM; Dedrick RL
Cancer Res; 1994 Oct; 54(19):5118-22. PubMed ID: 7923128
[TBL] [Abstract][Full Text] [Related]
6. Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates.
Stapleton SL; Thompson PA; Ou CN; Berg SL; McGuffey L; Gibson B; Blaney SM
Cancer Chemother Pharmacol; 2008 Apr; 61(4):647-52. PubMed ID: 17541590
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.
Berg SL; Reid J; Godwin K; Murry DJ; Poplack DG; Balis FM; Ames MM
J Pediatr Hematol Oncol; 1999; 21(1):26-30. PubMed ID: 10029808
[TBL] [Abstract][Full Text] [Related]
8. Plasma and cerebrospinal fluid pharmacokinetics of rebeccamycin (NSC 655649) in nonhuman primates.
Berg SL; Aleksic A; McGuffey L; Dauser R; Nuchtern J; Bernacky B; Blaney SM
Cancer Chemother Pharmacol; 2004 Aug; 54(2):127-30. PubMed ID: 15150671
[TBL] [Abstract][Full Text] [Related]
9. Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates.
Berg SL; Stone J; Xiao JJ; Chan KK; Nuchtern J; Dauser R; McGuffey L; Thompson P; Blaney SM
Cancer Chemother Pharmacol; 2004 Jul; 54(1):85-8. PubMed ID: 15042312
[TBL] [Abstract][Full Text] [Related]
10. Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates.
Stapleton SL; Reid JM; Thompson PA; Ames MM; McGovern RM; McGuffey L; Nuchtern J; Dauser R; Blaney SM
Cancer Chemother Pharmacol; 2007 Mar; 59(4):461-6. PubMed ID: 16855840
[TBL] [Abstract][Full Text] [Related]
11. Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates.
Berg SL; Brueckner C; Nuchtern JG; Dauser R; McGuffey L; Blaney SM
Cancer Chemother Pharmacol; 2007 May; 59(6):743-7. PubMed ID: 16953392
[TBL] [Abstract][Full Text] [Related]
12. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates.
Jacobs SS; Fox E; Dennie C; Morgan LB; McCully CL; Balis FM
Clin Cancer Res; 2005 Feb; 11(4):1669-74. PubMed ID: 15746072
[TBL] [Abstract][Full Text] [Related]
13. Plasma and cerebrospinal fluid pharmacokinetics of the novel tetrahydroisoquinoline EDL-155 in rats.
Song P; Ma F; Wang F; Wang X; Patil R; Ramagiri S; Orr WE; Miller DD; Geisert E; Yates CR
Cancer Chemother Pharmacol; 2008 May; 61(6):1037-44. PubMed ID: 17768626
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and distribution of SN 28049, a novel DNA binding anticancer agent, in mice.
Lukka PB; Paxton JW; Kestell P; Baguley BC
Cancer Chemother Pharmacol; 2010 May; 65(6):1145-52. PubMed ID: 19774378
[TBL] [Abstract][Full Text] [Related]
15. Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates.
Kilburn LB; Bonate PL; Blaney SM; McGuffey L; Nuchtern JG; Dauser R; Thompson P; Gibson BW; Berg SL
Cancer Chemother Pharmacol; 2009 Jul; 64(2):335-40. PubMed ID: 19043710
[TBL] [Abstract][Full Text] [Related]
16. Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates.
Warren KE; McCully C; Dvinge H; Tjørnelund J; Sehested M; Lichenstein HS; Balis FM
Cancer Chemother Pharmacol; 2008 Aug; 62(3):433-7. PubMed ID: 17960383
[TBL] [Abstract][Full Text] [Related]
17. Plasma pharmacokinetics and cerebrospinal fluid penetration of hypericin in nonhuman primates.
Fox E; Murphy RF; McCully CL; Adamson PC
Cancer Chemother Pharmacol; 2001; 47(1):41-4. PubMed ID: 11221960
[TBL] [Abstract][Full Text] [Related]
18. The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates.
Meany HJ; Fox E; McCully C; Tucker C; Balis FM
Cancer Chemother Pharmacol; 2008 Aug; 62(3):387-92. PubMed ID: 17932674
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.
Baker SD; Heideman RL; Crom WR; Kuttesch JF; Gajjar A; Stewart CF
Cancer Chemother Pharmacol; 1996; 37(3):195-202. PubMed ID: 8529278
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid and plasma pharmacokinetics of high doses of 1-beta-D-arabinofuranosylcytosine in nonhuman primates.
Lopez JA; Beardsley GP; Krikorian JG; Mortara RW; Agarwal RP
Cancer Res; 1983 Nov; 43(11):5190-3. PubMed ID: 6616454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
